Skip to main content

Table 4 Atypical antipsychotic AEs reported by physicians as clinically important and/or bothersome

From: Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

AEs, n (%) Clinically important
(n = 4)
Most clinically important
(n = 4)
Most bothersome to patients
(n = 4)
Metabolic syndrome a 4 (100) 4 (100) n/a
Weight gain 4 (100) 2 (50) 4 (100)
Reduced sexual desire or performance 4 (100) 1 (25) 2 (50)
Neutropenia b 3 (75) 3 (75) 1 (25)
Hyperglycemia b 3 (75) 2 (50) 0
EPS b 3 (75) 1 (25) 2 (50)
Hyperlipidemia 3 (75) 1 (25) 0
Akathisia 3 (75) 0 2 (50)
QT prolongation b 2 (50) 2 (50) 0
Major medical (seizures) 2 (50) 1 (25) 1 (25)
Hormonal 2 (50) 0 2 (50)
Hypotension 2 (50) 0 1 (25)
Cognitive issues 2 (50) 0 1 (25)
Major medical (diabetes) b 1 (25) 1 (25) 1 (25)
Hypertension 1 (25) 1 (25) 0
Low energy 1 (25) 0 1 (25)
Depressive symptoms 1 (25) 0 0
Flat/restricted affect 1 (25) 0 0
Somnolence/sedation 1 (25) 0 0
  1. Abbreviations: AE adverse event, EPS extrapyramidal symptoms, QT time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle
  2. a Reported as “most clinically important” in the group setting but not the individual task
  3. b Reported as “most clinically important” in the group setting and in the individual task